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Summary. The possible involvement of endogenous 
vasoactive intestinal peptide (VIP), cholecystokinin 
(CCK) and neurotensin (NT) in the control of thymocyte 
proliferation has been investigated in v ivo in the 
immature rat. For this task, we have studied the effects 
of the administration of selective antagonists of the 
receptors of the three neuropeptides on the mitotic index 
(%O of metaphase-arrested cells after vincristin injection) 
of thymocytes. Both CCK- and TN-receptor antagonists 
were ineffective. In contrast,  two VIP receptor 
antagonists (VIP-As) enhanced the mitotic index of 
thymocytes. VIP reversed the effect of VIP-As, but when 
administered alone it did not alter the mitotic activity of 
thymocytes. In light of these findings, we conclude that 
endogenous VIP exerts a maximal tonic inhibitory 
influence on the basa1 proliferative activity of rat 
thymocytes, while endogenous CCK and NT do not play 
a relevant modulatory role in this process. 
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lntroduction 
Severa1 regulatory neuropeptides and their receptors 
are present in the various components of the immune 
system, where they are able to modulate some important 
steps of the immune response. One of these steps is the 
proliferation of immune competent cells, among which 
are thymocytes (Savino et al., 1990; Dardenne and 
Savino, 1994; Head et al., 1998). 
The characteristic cytoarchitecture of the thymus is 
responsible for the maintenance of a unique 
microenvironment, which seems to be essential for the 
correct development of T cells (Brelinska and Warchol, 
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1997). This makes the use of the cell culture techniques 
unsuitable in the studies on the control of thymocyte 
proliferation. Moreover, the in vivo administration of 
exogenous neuropeptides do  not provide reliable 
information on the possible physiological role of their 
endogenous counterparts in the control of thymocyte 
proliferation. 
Bearing these limitations in mind, we designed 
experiments where the involvement of endogenous 
vasoactive intestinal peptide (VIP), cholecystokinin 
(CCK)/gastrin and neurotensin (NT), three neuro- 
peptides contained in the immune system (see 
Discussion), in the control of thymocyte proliferation 
has been investigated by administering rats with their 
selective receptor antagonists. 
Materials and methods 
Animals and reagents 
Immature (20-day-old) female Wistar rats were kept 
under a 12:12 h light-dark cycle (illumination onset at 
8:00 a.m.) at 2321 "C, and maintained on a standard diet 
and tap water ad libitum. 
VIP(1-28) rat, the VIP antagonists neurotensin(6- 
ll)/VIP(7-28 Moody et al., 1993) (VIP-Al), and [Ac- Z" 
~ i s l , ~ - ~ h e  , L ~ ~ ~ ~ , A ~ ~ ~ ~ ] v I P ( ~ - ~ ) G R F ( ~ - ~ ~ ) - N H  
(VIP-A2) (Gourlet et al., 1997), and pentagastrin ( P G ~  
were purchased from Bachem (Bubendorf, Switzerland). 
The pituitary adenylate cyclase-activating polypeptide 
(PACAP) antagonist PACAP(6-38) (Dickinson et al., 
1997) was obtained from Peninsula (St. Helens, UK). 
The CCK receptor A and B antagonists PD140,548 
(CCKA-A) and PD135,158 (CCKB-A), respectively 
(Hughes et al., 1990; Higginbottom et al., 1993) were 
obtained from Research Biochemical International 
(Natick, Mass., USA). NT and the NT antagonist (NT-A) 
[ D - T ~ ~ ~ I - N T  (Quirion et al., 1980), as well as other 
laboratory reagents were supplied by Sigma Chemical 
Co. (St. Louis, MO, USA). Vincristin was obtained from 
Gedeon-Richter (Budapest, Hungary). 
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Experimental procedures 
Groups of immature rats (n=6) were given three 
subcutaneous injections (28, 16 and 4 h before sacrifice) 
of the following chemicals dissolved in 0.2 m1 0.9% 
NaCl: (i) VIP andlor VIP-Al, VIP-A2 and PACAP(6-38) 
(20 nmoltkg); (ii) CCKA-A or CCKB-A alone or 
with PG (20 nmollkg); and (iii) NT andlor NT-A 
(40 nmoltkg). Control rats were injected with the 
saline vehicle. Al1 groups of animals received an 
intraperitoneal injection of vincristin (0.1 mg1100 g) 180 
min before the autopsy. Rats were decapitated at 11:OO 
a.m. 
Cell-proliferation assay 
Thymuses were promptly removed, and capsule- 
adjacent fragments were fixed in 2.5% glutaraldehyde, 
postfixed in 1% osmium tetroxide, and embedded in 
Araldite. Then, 0.5 pm-thick sections were cut, and 
stained with toluidine blue. The mitotic index (%o of 
metaphase-arrested cells) was calculated at x400, by 
counting 5,000 cells in the subcapsular zone (4-5 layers 
of cells) of each thymus. 
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Fig. 1. Lack of effects of endogenous CCK and PG on the proliferative 
activity of immature rat thymocytes. Bars are means + SEM (n = 6). 
Fig. 2. Lack of effect of endogenous NT on the proliferative activity 
immature rat thymocytes. Bars are means t SEM (n=6). 
Statistical analysis 
Individual results were averaged per experimental 
group, and SEM was calculated. The statistical 
comparison of the data was done by ANOVA, followed 
by the Multiple Range test of Duncan. 
Results 
Neither PG nor CCKA-A and CCKB-A, 
administered alone or together, affected the proliferative 
activity of rat thymocytes (Fig. 1). Likewise, NT andlor 
NT-A did not change thymocyte mitotic index (Fig. 2). 
VIP-A1 and VIP-A2 evoked a marked increase in the 
mitotic index of thymocytes, and the effect was 
prevented by the simultaneous injection of VIP. VIP and 
PACAP(6-38) were ineffective (Fig. 3). 
Discussion 
The present results indicate that of the three 
neuropeptides investigated only VIP plays a 
physiological role in the control of thymocyte 
proliferation. 
CCK is a 33-amino acid residue peptide, that is 
widely distributed in the central nervous system and 
peripheral organs and tissues, where it acts through two 
main subtypes of receptors, named CCKA and CCKB 
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Fig. 3. Effect of endogenous VIP on the proliferative activity of immature 
of rat thymocytes. Bars are means + SEM (n=6). *: p<0.01 from the 
respective control group. 
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receptors belonging to the G protein-coupled receptor 
superfamily. PG is a selective and potent agonist of 
CCKB receptors (Wank et al., 1992; Pisegna et al., 1993; 
Crawley and Corvin, 1994). The following evidence 
indicates that CCK is involved in immunomodulation. 
CCK and its receptors are present in the lymphoid tissue, 
including thymus (Felten et al., 1985; Weinberg et al., 
1997), and CCK restores thymus-dependent immune 
response in thymectomized mice and stimulates IgM- 
plaque forming cells (Belokrylov et al. ,  1990;  
Molchanova et al., 1992). Soder and Hellstrom (1987) 
reported that neither CCK nor PG affect the proliferative 
activity of human thymocytes or guinea pig T and B 
lymphocytes cultured in vitro. In contrast, De la Fuente 
et al. (1998) demonstrated an inhibitory effect of CCK 
on mitogen-induced proliferation of murine lymphocytes 
in vitro. Our previous in vivo studies (Malendowicz et 
al., 1999) showed a potent CCKA receptor-mediated 
stimulatory effect of exogenous CCK on the mitotic 
activity of rat thymocytes. However, our present findings 
strongly suggest that this effect of CCK has to be 
considered pharmacological in nature. In fact, neither 
CCKA-A and CCKB-A nor PG administration 
significantly affect thymocyte proliferation, thereby 
ruling out the possibility that endogenous CCK and 
gastrin play a relevant physiological modulatory role in 
this process. 
NT, a 13-amino acid residue peptide that acts 
through G protein-coupled receptors (Vincent et al., 
1999), is contained in the immune system. NT- 
immunoreactivity has been detected in the chicken (Atoji 
et al., 1996) and human thymus (Vanneste et al., 1997), 
and NT receptor mRNA in the medulla and epithelial 
cells of the chicken th mus (Atoji et al., 1996). NT was Y - found to stimulate [ H] thymidine incorporation in 
human thymocytes and to inhibit it in guinea pig lymph 
node cells (Soder and Hellstrom, 1987). Our present 
findings cast doubts on the involvement of endogenous 
NT in the regulation of thymocyte mitogenic activity in 
the rat, inasmuch as neither NT nor NT-A affect it. This 
observation appears to accord well with the reported lack 
of NT-immunoreactivity in the rat thymus (Muller and 
Weihe, 1991; Atoji et al., 1996). 
VIP is a 28-amino acid residue peptide, that displays 
a remarkable amino acid-sequence homology with 
PACAP (Nussdorfer and Malendowicz, 1998). VIP and 
PACAP act through G protein-coupled receptors, named 
VIP-PACAP receptors. Three subtypes of VIP-PACAP 
receptors have been identified so far: the PAC1, VPACl 
and VPAC2 receptors (Harmar et al., 1998). Their 
binding potency is as follows: PAC1, PACAP>>>VIP; 
VPAC1, VIP>PACAP; and VPAC2, VIP=PACAP 
(Nussdorfer and Malendowicz, 1998). VIP is abundant 
in the immune system (Martinez et al., 1999) and VIP- 
ergic fibers are present in the subcapsular cortex, 
interlobular septa and accompanying vasculature of the 
thymus (Gomariz et al., 1990, 1993; Kendall and Al- 
Shawaf, 1991; Müller and Weihe, 1991; Bellinger et al., 
1997). Lymphocytes and thymocytes are provided with 
VPACl and VPAC2 receptors (Delgado et al., 1996). VIP 
has been reported to inhibit [3~]-thymidine uptake by 
non-activated and activated human thymocytes, as well 
as basa1 DNA synthesis in rat spleen cells (Soder and 
Hellstrom, 1987; Yiangou et al., 1990; Boudard and 
Bastide, 1991; De la Fuente et al., 1996; Ganea, 1996; 
Pankhaniya et al., 1998). 
The present demonstration that VIP-As enhance the 
mitotic activity of rat thymocytes, while VIP per se is 
ineffective strongly suggests that endogenous VIP exerts 
a maximal tonic inhibition of the thymocyte proliferative 
activity. This tonic inhibition is conceivably mediated by 
the VPACl receptor subtype. In fact, the selective 
antagonist of VPACl receptors VIP-A2 (Gourlet et al., 
1997) raises thymocyte proliferation, while the selective 
antagonist of PACl receptors PACAP(8-36), that also 
interacts with VPAC2 receptors (Dickinson et al., 1997), 
is ineffective. The physiological and physiopathological 
relevance of this VIP effect on the rat thymus growth 
remains to be investigated. 
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